Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2001

View Archived Issues

Pravastatin highlighted at ACC scientific sessions

Welfide and Mitsubishi-Tokyo Pharmaceuticals to merge

FDA requests additional information to support Bexxar BLA

Leiras and Nycomed Pharma create joint venture

Ligand updates Targretin development programs in NSCLC, breast cancer and psoriasis

BNP levels reliably detect LV dysfunction in diabetics

MediGene's NV-1020 shows good safety profile in phase I

Experiments in human arteries suggest potential of SLV-306 in CHD

Medco's new stress imaging agent induces coronary hyperemia with few adverse effects

AstraZeneca's Nexium for erosive esophagitis launched in U.S.

L-Arginine has beneficial effects in a range of cardiovascular disorders

Roche seeks FDA approval for Xenical as adjunct in type 2 diabetes

First well-controlled trial of cardiovascular gene therapy discussed at late-breaking ACC session

Novel NK2 antagonist effective in guinea pig models of asthma symptoms

KAD-1229 more effective than nateglinide or voglibose against postprandial hyperglycemia

Calyx commences phase II trial of CLX-0901 in type 2 diabetes

OPC-51803, a new vasopressin V2 agonist, characterized in dogs

Development of Immunex's Enbrel for CHF halted

Versicor begins phase III trial with V-echinocandin for treatment of esophageal candidiasis

ACC news: halofuginone reduces neointimal hyperplasia in response to coronary stenting in pigs

Multiple-cytokine fusion proteins prepared at Lexigen for use in cancer

Anxiolytic isoquinolines disclosed by Egis researchers

Two patents issued to Novuspharma cover new antitumor agents

Biochemie presents new antibacterial mutilin derivatives

Cyclic and acyclic amine derivatives under study at Vertex for use in neurological disorders

Aventis antitumor agents act by inhibiting Ras farnesylation

Hungarian scientists claim new series of heterocyclic angiogenesis inhibitors

Neuropeptide Y receptor antagonists designed at Ortho-McNeil

Morphochem and Aventis to develop novel diabetes treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...